Literature DB >> 32447488

Consensus document: management of heart failure in type 2 diabetes mellitus.

Upendra Kaul1, Saumitra Ray2, D Prabhakar3, Arun Kochar4, Kamal Sharma5, Prakash Kumar Hazra6, Subhash Chandra7, Dharmesh Ramakant Bhai Solanki8, Anjan Lal Dutta9, Viveka Kumar10, M Srinivas Rao11, Abraham Oomman12, Sameer Dani13, Brian Pinto14, T R Raghu15.   

Abstract

Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual burden on patients. In addition, it concisely narrates the types of HF, the different treatment algorithms, and recommendations for physicians to comprehensively manage such patients.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diagnosis; Drug; Heart failure; Trials; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2021        PMID: 32447488     DOI: 10.1007/s10741-020-09955-7

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  114 in total

1.  Diabetes lowers six-minute walk test performance in heart failure.

Authors:  Lee Ingle; Priya Reddy; Andrew L Clark; John G F Cleland
Journal:  J Am Coll Cardiol       Date:  2006-04-17       Impact factor: 24.094

2.  One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India.

Authors:  Sivadasanpillai Harikrishnan; Ganapathi Sanjay; Anubha Agarwal; N Pratap Kumar; K Krishna Kumar; Charantharayil Gopalan Bahuleyan; Govindan Vijayaraghavan; Sunitha Viswanathan; Madhu Sreedharan; R Biju; N Rajalekshmi; Tiny Nair; Krishnan Suresh; Panniyammakal Jeemon
Journal:  Am Heart J       Date:  2017-04-02       Impact factor: 4.749

3.  Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study.

Authors:  Hisham Dokainish; Koon Teo; Jun Zhu; Ambuj Roy; Khalid F AlHabib; Ahmed ElSayed; Lia Palileo-Villaneuva; Patricio Lopez-Jaramillo; Kamilu Karaye; Khalid Yusoff; Andres Orlandini; Karen Sliwa; Charles Mondo; Fernando Lanas; Dorairaj Prabhakaran; Amr Badr; Mohamed Elmaghawry; Albertino Damasceno; Kemi Tibazarwa; Emilie Belley-Cote; Kumar Balasubramanian; Shofiqul Islam; Magdi H Yacoub; Mark D Huffman; Karen Harkness; Alex Grinvalds; Robert McKelvie; Shrikant I Bangdiwala; Salim Yusuf
Journal:  Lancet Glob Health       Date:  2017-05-03       Impact factor: 26.763

4.  Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure.

Authors:  M Egstrup; C N Kistorp; M Schou; D E Høfsten; J E Møller; C D Tuxen; I Gustafsson
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-08-16       Impact factor: 6.875

Review 5.  Heart failure: epidemiology and prevention in India.

Authors:  Mark D Huffman; Dorairaj Prabhakaran
Journal:  Natl Med J India       Date:  2010 Sep-Oct       Impact factor: 0.537

6.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).

Authors:  Søren L Kristensen; Ulrik M Mogensen; Pardeep S Jhund; Mark C Petrie; David Preiss; Sithu Win; Lars Køber; Robert S McKelvie; Michael R Zile; Inder S Anand; Michel Komajda; John S Gottdiener; Peter E Carson; John J V McMurray
Journal:  Circulation       Date:  2017-01-04       Impact factor: 29.690

7.  Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry.

Authors:  Sivadasanpillai Harikrishnan; Ganapathi Sanjay; Thajudeen Anees; Sunitha Viswanathan; Govindan Vijayaraghavan; Charantharayil G Bahuleyan; Madhu Sreedharan; Ramabhadran Biju; Tiny Nair; Krishnan Suresh; Ashok C Rao; Dae Dalus; Mark D Huffman; Panniyammakal Jeemon
Journal:  Eur J Heart Fail       Date:  2015-05-23       Impact factor: 15.534

8.  Diabetes and cardiovascular risk factors: the Framingham study.

Authors:  W B Kannel; D L McGee
Journal:  Circulation       Date:  1979-01       Impact factor: 29.690

9.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

Review 10.  The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Authors:  Anne Pernille Ofstad; Dan Atar; Lars Gullestad; Gisle Langslet; Odd Erik Johansen
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

View more
  2 in total

1.  Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes.

Authors:  Gudrun Höskuldsdóttir; Stefan Franzén; Katarina Eeg-Olofsson; Björn Eliasson
Journal:  Sci Rep       Date:  2022-07-11       Impact factor: 4.996

Review 2.  The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.

Authors:  Xiaohui Pan; Shishi Xu; Juan Li; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-01       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.